NCT05272605View on ClinicalTrials.gov

Safety and Immune Response of Adjuvanted SARS-CoV-2 (COVID-19) Beta Variant RBD Recombinant Protein (DoCo-Pro-RBD-1 + MF59®) and mRNA (MIPSCo-mRNA-RBD-1) Vaccines in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

April 5, 2022

Primary Completion Date

April 19, 2023

Study Completion Date

April 19, 2023

Conditions
SARS-CoV-2
Interventions
BIOLOGICAL

Adjuvanted SARS-CoV-2 beta variant RBD recombinant protein vaccine (DoCo-Pro-RBD-1 + MF59)

Single booster dose in healthy adults previously vaccinated with two doses of CominartyTM (BNT162b2 \[mRNA\]) or VaxzevriaTM (ChAdOx1-S) COVID-19 and a third booster dose of either ComirnatyTM or SpikevaxTM vaccines.

BIOLOGICAL

SARS-CoV-2 beta variant RBD mRNA vaccine

Single booster dose in healthy adults previously vaccinated with two doses of CominartyTM (BNT162b2 \[mRNA\]) or VaxzevriaTM (ChAdOx1-S) COVID-19 and a third booster dose of either ComirnatyTM or SpikevaxTM vaccines.

OTHER

Normal Saline

Placebo comparator

Trial Locations (2)

3010

Vaccine and Immunisation Research Group, Doherty Institute, University of Melbourne, Melbourne

3052

Royal Melbourne Hospital, Victorian Infectious Diseases Service (VIDS), Melbourne

Sponsors

Collaborators (1)

Southern Star Research
All Listed Sponsors
collaborator

Southern Star Research

INDUSTRY

lead

University of Melbourne

OTHER

NCT05272605 - Safety and Immune Response of Adjuvanted SARS-CoV-2 (COVID-19) Beta Variant RBD Recombinant Protein (DoCo-Pro-RBD-1 + MF59®) and mRNA (MIPSCo-mRNA-RBD-1) Vaccines in Healthy Adults | Biotech Hunter | Biotech Hunter